Abstracts tagged "axial spondyloarthritis"

Abstract Number: 580 • 2014 ACR/ARHP Annual Meeting
MRI Is Often Negative in Clinically Suspected Non-Radiographic Axial Spondyloarthritis
M.L. John¹, M.a.C. van der Weijden^1,2, C.M.a. van der Bijl¹, S.T.G. Bruijnen¹, C.J. van der Laken¹, M.T. Nurmohamed^1,2 and I.E. van der Horst-Bruinsma¹, ¹Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ²Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands
Background/Purpose The diagnosis of ankylosing spondylitis (AS) is based on disease specific bone damage seen on plain radiography of the pelvis. Recent developments in magnetic…
Abstract Number: 2578 • 2014 ACR/ARHP Annual Meeting
Disease Activity Is the Major Determinant of Quality of Life and Physical Function in Patients with Early Axial Spondyloarthritis. Results from the Esperanza Cohort.
Cristina Fernández-Carballido¹, Victoria Navarro-Compán², Mireia Moreno³, Xavier Juanola⁴, Juan Mulero⁵ and Eugenio De Miguel⁶, ¹Rheumatology, University General Hospital Elda, Elda (Alicante), Spain, ²Rheumatology, University Hospital La Paz and Leiden University Medical Center, Madrid, Spain, ³Rheumatology, University Hospital Parc Taulí, Sabadell, Spain, ⁴Rheumatology, University Hospital Bellvitge, Barcelona, Spain, ⁵Rheumatology, University Hospital Puerta de Hierro, Majadahonda (Madrid), Spain, ⁶Rheumatology, University Hospital La Paz - IdiPaz, Madrid, Spain
Background/Purpose : Main objective: to describe health related quality of life (HRQoL), physical function (PF) and spinal mobility (SM) in patients with early axial Spondyloarthritis…
Abstract Number: 562 • 2014 ACR/ARHP Annual Meeting
Clinical Response and Remission in Patients with Non-Radiographic Axial Spondyloarthritis after Three Years of Adalimumab Therapy
Désirée M. van der Heijde¹, Joachim Sieper², Walter P. Maksymowych³, Dominique L. Baeten⁴, Yinglin Xia⁵, Jaclyn K. Anderson⁵ and Aileen L. Pangan⁵, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁴Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: Adalimumab (ADA) has been previously shown to be effective for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) patients (pts) in the ABILITY-1 trial.1 Week…
Abstract Number: 2577 • 2014 ACR/ARHP Annual Meeting
The Ankylosing Spondylitis Disease Activity Score More Closely Reflects MRI Parameters of Sacroiliitis Than the Bath Ankylosing Spondylitis Disease Activity Index in Patients with Non-Radiographic Axial Spondyloarthritis
Walter P. Maksymowych¹, S Wichuk¹, H Jones², A Szumski³, L Marshall², J Bukowski² and RG Lambert⁴, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Pfizer Inc., Collegeville, PA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Radiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Validation of clinical measures of disease in non-radiographic axial SpA (nr-axSpA) has been limited, especially using inflammatory and structural lesions on MRI as gold…
Abstract Number: 577 • 2014 ACR/ARHP Annual Meeting
A Substantial Decrease in Work Productivity and Physical Health-Related Quality of Life in Chronic Back Pain of Recent Onset: Data from the SPACE-Cohort
A Roeterink¹, M de Hooge², R. van den Berg², H Dagfinrud³, M Turina⁴, M. van Oosterhout⁵, D. van der Heijde¹ and F van Gaalen², ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Oslo City Dept of Rheumat, Diakonhjemmet Hospital, Oslo, Norway, ⁴Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁵Groene Hartziekenhuis, Gouda, Netherlands
Background/Purpose: Ankylosing spondylitis is associated with work productivity (WP) loss and a decreased health-related quality of life (HRQoL). Little is known about WP loss and…
Abstract Number: 2558 • 2014 ACR/ARHP Annual Meeting
Etanercept Increases Bone Mineral Density in Ankylosing Spondylitis, but Does Not Prevent Vertebral Fractures
M.a.C. van der Weijden^1,2, J.C. van Denderen², W.F. Lems¹, M.T. Nurmohamed^1,2, B.a.C Dijkmans^1,2 and I.E. van der Horst-Bruinsma¹, ¹Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ²Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands
Background/Purpose Ankylosing spondylitis (AS) is characterized by chronic inflammation often leading to ankylosis of the spine, but also by a decrease of bone mineral density…
Abstract Number: 566 • 2014 ACR/ARHP Annual Meeting
Structural Progression of the Spine Measured By X-Ray in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol over 96 Weeks, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Désirée M. van der Heijde¹, Walter P. Maksymowych², Robert B. M. Landewé³, Christian Stach⁴, Owen Davies⁵, Tommi Nurminen⁴ and Jürgen Braun⁶, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴UCB Pharma, Monheim, Germany, ⁵UCB Pharma, Slough, United Kingdom, ⁶Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany
Background/Purpose The impact of certolizumab pegol (CZP) on clinical and Magnetic Resonance Imaging outcomes in patients (pts) with axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS)…
Abstract Number: 2560 • 2014 ACR/ARHP Annual Meeting
Sustained Improvements in Workplace and Household Productivity and Social Participation with Certolizumab Pegol over 96 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Desiree van der Heijde¹, Juergen Braun², Martin Rudwaleit³, Oana Purcaru⁴ and Arthur Kavanaugh⁵, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Endokrinologikum, Berlin, Germany, ⁴Allee De La Recherche 60, UCB Pharma, Anderlecht, Belgium, ⁵University of California San Diego, La Jolla, CA
Background/Purpose Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS, meeting modified New York criteria) and axSpA with no sacroiliitis on X-ray (non-radiographic axSpA, nr-axSpA). Previous…
Abstract Number: 565 • 2014 ACR/ARHP Annual Meeting
Effect of Certolizumab Pegol over 96 Weeks of Treatment on Inflammation of Spine and Sacroiliac Joints Measured By Magnetic Resonance Imaging in Patients with Axial Spondyloarthritis
Jürgen Braun¹, Walter P. Maksymowych², Robert B. M. Landewé³, Christian Stach⁴, Owen Davies⁵, Tommi Nurminen⁴ and Desiree van der Heijde⁶, ¹Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴UCB Pharma, Monheim, Germany, ⁵UCB Pharma, Slough, United Kingdom, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose Previous results from RAPID-axSpA (NCT01087762) demonstrated that certolizumab pegol (CZP) reduced inflammation in the sacroiliac joints (SIJ) and spine, as assessed by Magnetic Resonance…
Abstract Number: 2324 • 2014 ACR/ARHP Annual Meeting
Only 30% Rheumatologists Collect Basdai in Patients with Axial Spa in Daily Practice: The Potential Role of a Consensual Meeting to Improve It
Hélène Che^1,2, Adrien Etcheto^2,3, Emmanuelle Dernis Labous^4,5, Henri Nataf⁵, Patrick Boumier⁵, Philippe Breuillard⁵, Marianne Durandin-Truffinet⁵, Jacques Fechtenbaum^2,5, Veronique Gaud-Listrat^2,5, Bernard Giraud⁵, Christophe Hudry^2,5, Sylvain La Batide Alanore⁵, Patricia Le Devic⁵, Patrick Le Goux⁵, Agnes Lebrun^2,5, Emmanuel Maheu⁵, Bertrand Moura⁵, Minh Nguyen^2,5, Antoinette Sacchi⁵, Xavier Ayral^5,6, Anne Blanchais^2,5, Severine Neveu^2,5, Maxime Dougados^2,5,7 and Anna Molto^2,5,7, ¹Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ²Université Paris René Descartes and Hôpital Cochin, Paris, France, ³Cochin Hospital, Paris Descartes University, Paris, France, ⁴Rhumatologie, Ch Du Mans, Le Mans, France, ⁵Réseau Hôpital et Ville en Rhumatologie (RHEVER) Network, Paris, France, ⁶Université Paris René Descartes and Hôpital Cochin, paris, France, ⁷INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France
Background/Purpose The current recommendations for optimal monitoring of axial spondyloarthritis (SpA) are to assess regularly disease activity. The two proposed tools comprise clinical aspects as…
Abstract Number: 544 • 2014 ACR/ARHP Annual Meeting
Observed Incidence Rates of Uveitis over 96 Weeks of Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis
James T. Rosenbaum^1,2, Martin Rudwaleit³, Robert B. M. Landewé⁴, Helena Marzo-Ortega^5,6, Joachim Sieper⁷, Désirée M. van der Heijde⁸, Owen Davies⁹, Christian Stach¹⁰, Tommi Nurminen¹⁰ and Atul A. Deodhar¹¹, ¹OHSU, Portland, OR, ²Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR, ³Endokrinologikum, Berlin, Germany, ⁴Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁵Leeds Teaching Hospitals NHS Trust and NIHR Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁶University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁷Rheumatology Department,, University Hospital Charité, Berlin, Germany, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Monheim, Germany, ¹¹Oregon Health and Sciences University, Portland, OR
Background/Purpose: Axial spondyloarthritis (axSpA) is characterized by inflammation in the spine and sacroiliac joints, but can also manifest as inflammation at extra-spinal sites, most commonly…
Abstract Number: 2302 • 2014 ACR/ARHP Annual Meeting
Classification of Juvenile Spondyloarthropathies According to ASAS Criteria
Marìa M. Katsicas¹ and Ricardo A. G. Russo², ¹Immunology & Rheumatology., Hospital de Pediatrìa Garrahan, Buenos Aires, Argentina, ²Immunology & Rheumatology, Hospital de Pediatria Garrahan, Buenos Aires, Argentina
Background/Purpose The juvenile spondyloarthropathies (JSpA) are a group of related seronegative rheumatic diseases characterized by involvement of the axial , peripheral large joints and entheses.…
Abstract Number: 543 • 2014 ACR/ARHP Annual Meeting
Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol
Désirée M. van der Heijde¹, Atul A. Deodhar², Owen Davies³, Tommi Nurminen⁴ and Martin Rudwaleit⁵, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR, ³UCB Pharma, Slough, United Kingdom, ⁴UCB Pharma, Monheim, Germany, ⁵Endokrinologikum, Berlin, Germany
Background/Purpose: Early response to anti-TNF therapy has been shown to be a strong predictor of good long-term outcomes in ankylosing spondylitis (AS).1 However, early identification…
Abstract Number: 1895 • 2014 ACR/ARHP Annual Meeting
Sacroiliitis at Diagnosis in Children with Juvenile Spondyloarthritis
Pamela Weiss¹, Rui Xiao^2,3 and Nancy Chauvin⁴, ¹Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ²Department of Pediatrics, Division of Biostatistics, Children's Hospital of Philadelphia, Philadelphia, PA, ³Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁴Radiology, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose The prevalence of sacroiliitis in children with juvenile spondyloarthritis (JSpA) at diagnosis is unknown. We aimed to evaluate: 1) the prevalence of sacroiliitis at…
Abstract Number: 1893 • 2014 ACR/ARHP Annual Meeting
Substantial Structural Lesions on MRI in the Sacroiliac Joints of Patients with Non-Radiographic Axial Spondyloarthritis Even in the Absence of MRI Inflammation
Walter P. Maksymowych¹, S Wichuk¹, H Jones², A Szumski³, L Marshall⁴, J Bukowski⁵ and RG Lambert⁶, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Inflammation Immunology Disease Group, Pfizer Inc., Collegeville, PA, ⁵Pfizer Inc., Collegeville, PA, ⁶Radiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Treatment of axial SpA is increasingly aimed at intervention early in the disease course before radiographic sacroiliitis has appeared and when response to treatment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].